Among them, the pre-clinical observation that the activation of key transducers of metabolic signals—such as the PI3K/AKT/mTOR signaling pathway—confer endocrine resistance, has guided therapeutic strategies combining endocrine therapy with mTOR inhibitors to successfully manage endocrine-resistant breast cancer in clinical settings [16,17,18,19,20]. This evidence concerns the gene MTOR and breast cancer.